{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:59:43Z","timestamp":1793923183624,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Positive ascites cytology is a strong prognostic factor in patients with early-stage ovarian cancer (OvCa). However, limited information is currently available on the impact of positive ascites cytology on patient prognoses under each clinical background. We herein investigated the comprehensive impact of positive ascites cytology on patients with epithelial OvCa and the effectiveness of additional therapeutic interventions, including complete staging surgery and chemotherapy. Among 4730 patients with malignant ovarian neoplasms, retrospectively identified in multiple institutions, 1906 with epithelial OvCa were included. In the investigation of its effects on clinical factors using a multivariate analysis, positive ascites cytology correlated with a poor prognosis. Positive ascites cytology had a significantly worse prognosis than those with negative cytology in all subgroups except for patients with stage IV tumors and a mucinous histology. Chemotherapy may be effective in reducing the negative impact of positive ascites cytology on the prognosis of patients in terms of progression-free and overall survivals, while complete staging surgery did not improve the prognosis of patients with positive ascites cytology. Collectively, our findings suggested that positive ascites cytology had a negative impact on the prognosis of patients with epithelial OvCa, but not those with stage IV tumors or a mucinous histology.<\/jats:p>","DOI":"10.1038\/s41598-021-93718-3","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T06:11:30Z","timestamp":1627279890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Masato","family":"Yoshihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kitami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Iyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Tano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"93718_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"93718_CR2","unstructured":"2016 Annual report of the Committee on Gynecologic Oncology, Acta Obstet. Gynaecol. Jpn. 70, 1372\u2013444 (2018)."},{"key":"93718_CR3","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz, A. P. et al. Carcinoma of the Ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 95, S161\u2013S192 (2006).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"93718_CR4","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.3802\/jgo.2018.29.e37","volume":"29","author":"S Hirose","year":"2018","unstructured":"Hirose, S. et al. Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer. J. Gynecol. Oncol. 29, e37 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"93718_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","volume":"290","author":"F Zeppernick","year":"2014","unstructured":"Zeppernick, F. & Meinhold-Heerlein, I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch. Gynecol. Obstet. 290, 839\u2013842 (2014).","journal-title":"Arch. Gynecol. Obstet."},{"key":"93718_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat, J. & FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124, 1\u20135 (2014).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"93718_CR7","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/cncr.23390","volume":"112","author":"JK Chan","year":"2008","unstructured":"Chan, J. K. et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: A gynecologic oncology group study. Cancer 112, 2202\u20132210 (2008).","journal-title":"Cancer"},{"key":"93718_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11912-014-0389-x","volume":"16","author":"J Brown","year":"2014","unstructured":"Brown, J. & Frumovitz, M. Mucinous tumors of the ovary: Current thoughts on diagnosis and management. Curr. Oncol. Rep. 16, 389 (2014).","journal-title":"Curr. Oncol. Rep."},{"key":"93718_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2011.12.424","volume":"125","author":"AA Storms","year":"2012","unstructured":"Storms, A. A. et al. Mucinous tumors of the ovary: Diagnostic challenges at frozen section and clinical implications. Gynecol. Oncol. 125, 75\u201379 (2012).","journal-title":"Gynecol. Oncol."},{"key":"93718_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter, P. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med. 380, 822\u2013832 (2019).","journal-title":"N. Engl. J. Med."},{"key":"93718_CR11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/cancers13061352","volume":"13","author":"K Mogi","year":"2021","unstructured":"Mogi, K. et al. Ovarian cancer-associated mesothelial cells: Transdifferentiation to minions of cancer and orchestrate developing peritoneal dissemination. Cancers 13, 1352 (2021).","journal-title":"Cancers"},{"key":"93718_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/AOG.0000000000003507","volume":"134","author":"K Matsuo","year":"2019","unstructured":"Matsuo, K. et al. Intraoperative capsule rupture, postoperative chemotherapy, and survival of women with stage I epithelial ovarian cancer. Obstet. Gynecol. 134, 1017\u20131026 (2019).","journal-title":"Obstet. Gynecol."},{"key":"93718_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","volume":"26","author":"S Pradeep","year":"2014","unstructured":"Pradeep, S. et al. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell 26, 77\u201391 (2014).","journal-title":"Cancer Cell"},{"key":"93718_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1084\/jem.20180765","volume":"216","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 216, 688\u2013703 (2019).","journal-title":"J. Exp. Med."},{"key":"93718_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10585-016-9821-y","volume":"33","author":"I Matte","year":"2016","unstructured":"Matte, I. et al. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin. Exp. Metastasis 33, 839\u2013852 (2016).","journal-title":"Clin. Exp. Metastasis"},{"key":"93718_CR16","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/cncr.11345","volume":"97","author":"VW Chen","year":"2003","unstructured":"Chen, V. W. et al. Pathology and classification of ovarian tumors. Cancer 97, 2631\u20132632 (2003).","journal-title":"Cancer"},{"key":"93718_CR17","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology; Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 1. 2017. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (2017). Retrieved 22 June 2017."},{"key":"93718_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10147-016-0985-x","volume":"21","author":"S Komiyama","year":"2016","unstructured":"Komiyama, S. et al. Japan society of gynecologic oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. Int. J. Clin. Oncol. 21, 435\u2013446 (2016).","journal-title":"Int. J. Clin. Oncol."},{"key":"93718_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/annonc\/mdn059","volume":"19","author":"S Suzuki","year":"2008","unstructured":"Suzuki, S. et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?. Ann. Oncol. 19, 1284\u20131287 (2008).","journal-title":"Ann. Oncol."},{"key":"93718_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin, G. J. et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int. J. Gynecol. Cancer 21, 419\u2013423 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"93718_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum, P. R. & Rubin, D. B. Reducing bias in observational studies using subclassification on the propensity score. Am. J. Stat. Assoc. 79, 516\u2013524 (1984).","journal-title":"Am. J. Stat. Assoc."},{"key":"93718_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s13054-015-1086-3","volume":"19","author":"M Yoshihara","year":"2015","unstructured":"Yoshihara, M. et al. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: A retrospective study. Crit. Care 19, 369 (2015).","journal-title":"Crit. Care"},{"key":"93718_CR23","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.3802\/jgo.2019.30.e102","volume":"30","author":"M Yoshihara","year":"2019","unstructured":"Yoshihara, M. et al. Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: A propensity score analysis. J. Gynecol. Oncol. 30, e102 (2019).","journal-title":"J. Gynecol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93718-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93718-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93718-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:45:27Z","timestamp":1670049927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93718-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93718-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-431054\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15154"}}